Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook ...

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report), with a price target of $44.00. The company ...